Cardiac Amyloidosis Market Set to Expand from USD 2.18 Billion in 2024 to USD 5 Billion by 2035, Exhibiting a CAGR of 7.8%

WiseGuy Reports, Nov. 2025 (Press Release) – The Cardiac Amyloidosis Market Global Outlook:

Cardiac Amyloidosis Market Trends 2025 and Competitor Growth Analysis Report By Type of Cardiac Amyloidosis (AL Amyloidosis, ATTR Amyloidosis, Carbamyloidosis, Senile Systemic Amyloidosis), By Diagnosing Method (Biopsy, Nuclear Imaging, Echocardiography, Cardiac MRI), By Treatment Type (Chemotherapy, Targeted Therapy, Stem Cell Transplantation, Supportive Care), By End User (Hospitals, Clinics, Home Healthcare, Research Institutions) and By Regional, Share, Industry Size, Developments and Forecast to 2035

Cardiac Amyloidosis Market: Rising Demand for Innovative Diagnostics and Targeted Therapies Driving Market Growth

The Cardiac Amyloidosis Market is gaining significant traction as the prevalence of amyloidosis continues to increase worldwide. According to the latest market data, the global Cardiac Amyloidosis Market Size was valued at USD 2.18 billion in 2024 and is projected to reach USD 5.0 billion by 2035, expanding at a robust CAGR of 7.8% during the forecast period (2025–2035). This impressive market growth is primarily driven by advancements in diagnostic technologies, expanding treatment options, and growing awareness among healthcare providers.

Market Overview and Key Players

The global Cardiac Amyloidosis Market is characterized by continuous innovation from leading pharmaceutical and biotechnology companies. Major market key manufacturers include Daiichi Sankyo, Genentech, Sanofi, Novartis, Pfizer, Merck & Co., Bristol-Myers Squibb, Ionis Pharmaceuticals, Amgen, Eisai, AstraZeneca, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, and Regeneron Pharmaceuticals. These industry leaders are investing heavily in market research and development to introduce new treatment modalities that address unmet clinical needs.

The market segment includes Type of Cardiac Amyloidosis, Diagnosing Method, Treatment Type, and End User. The AL (light-chain) amyloidosis segment dominates the market share due to its higher prevalence and growing diagnostic accuracy. In contrast, the ATTR (transthyretin) amyloidosis segment is expected to witness substantial market growth dynamics over the next decade, supported by the approval of novel therapeutics.

👉 Sample Report: Get a comprehensive view of the latest Cardiac Amyloidosis Market Trends and Market Business Insights here – https://www.wiseguyreports.com/sample-request?id=744494

Segmental Analysis and Market Trends

Based on the market segment, the diagnostic segment is projected to record steady growth due to advancements in imaging technologies such as cardiac MRI and nuclear scintigraphy. The treatment segment is evolving with the introduction of disease-modifying therapies that target the root cause of amyloid accumulation. Hospitals and specialty clinics lead the end-user segment, attributed to the growing number of patient visits for cardiac evaluations and treatment.

Emerging market trends highlight the growing focus on precision medicine and the integration of artificial intelligence in diagnostic workflows. Additionally, collaborations between academic institutions and pharmaceutical firms are enhancing the development of effective therapeutic agents.

Key Market Dynamics

The Cardiac Amyloidosis Market analysis underscores several key drivers fueling growth. These include the increasing prevalence of amyloidosis globally, growing awareness among healthcare professionals, and supportive regulatory approvals for innovative drugs. The introduction of RNA-based therapies and advanced diagnostic imaging technologies are further expanding market opportunities. Moreover, the shift toward early diagnosis and treatment personalization is expected to reshape the market outlook over the coming years.

Challenges include the high cost of therapies and limited access to advanced diagnostics in low- and middle-income regions. However, continuous efforts by top market companies to develop cost-effective solutions are mitigating these challenges, paving the way for sustainable market expansion.

Regional Analysis

Regionally, North America dominates the Cardiac Amyloidosis Market Regional Share, accounting for a major portion of global revenue due to the presence of advanced healthcare infrastructure and key pharmaceutical players. Europe follows closely, with significant market developments driven by government initiatives and clinical research funding. The Asia-Pacific (APAC) region is anticipated to witness the fastest market growth, supported by increasing healthcare investments in countries like China, Japan, and India. Meanwhile, South America and the Middle East & Africa (MEA) are emerging regions showing potential due to improved access to cardiac care services.

👉 Purchase Report: Access in-depth market forecast, market projections, and detailed market data here – https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=744494

Recent Developments

• Pfizer announced advancements in tafamidis-based therapies targeting transthyretin amyloidosis, strengthening its market position.
• Alnylam Pharmaceuticals expanded its clinical trials for RNAi therapeutics aimed at ATTR cardiomyopathy.
• Ionis Pharmaceuticals collaborated with AstraZeneca to develop next-generation antisense therapies.
• Takeda Pharmaceutical invested in novel imaging technologies to enhance early amyloidosis detection.
• Novartis initiated patient access programs in emerging economies to improve treatment availability.

Reasons to Buy the Report

1. Gain an in-depth understanding of the Cardiac Amyloidosis Market analysis and competitive landscape.
2. Access reliable market forecast data and growth projections through 2035.
3. Identify market trends shaping diagnostic and therapeutic innovations.
4. Understand market segment performance and regional dynamics.
5. Leverage market business insights for strategic decision-making and investment planning.

Key Highlights

The Cardiac Amyloidosis Market Global Outlook remains positive, with sustained market growth dynamics anticipated across all regions. Increasing diagnostic precision, the introduction of targeted therapies, and expanding patient access to treatments are set to transform the industry. Supported by technological innovation and active participation from market top companies, the future of the Cardiac Amyloidosis Market promises improved patient outcomes and profitable growth opportunities.

Browse Complete Premium Cardiac Amyloidosis Market Research Report: https://www.wiseguyreports.com/reports/cardiac-amyloidosi-market

Reasons To Buy The Cardiac Amyloidosis Market Report:

➼ In-depth analysis of the Cardiac Amyloidosis Market on the global and regional levels.

➼ Major changes in market dynamics and competitive landscape.

➼ Segmentation on the basis of type, application, geography, and others.

➼ Historical and future market research in terms of size, share growth, volume, and sales.

➼ Major changes and assessment in market dynamics and developments.

➼ Emerging key segments and regions

➼ Key business strategies by major market players and their key methods

Related Research insights from Wise Guy Reports:

Vigreux Distillation Column Market

Spina Bifida Treatment Market

Soluble Hemostatic Gauze Market

Ready-to-Use Antibodies Market

STD Rapid Detection Kit Market

Sample Diluter Market

Sterile Fill Finish CMO Market

Rodent Brain Matrices Market

Spine Dynamic Stabilization System Market

Spinal Muscular Atrophy SMA Treatment Market

Sodium Acetate Ringer's Injection for Injection Market

Single Cell Culture Slides Market

Sterile Hyaluronic Acid Market

Schizophrenia-Related Peptide Market

Stretcher Fixation Straps Market

About US:

Wise Guy Reports is pleased to introduce itself as a leading provider of insightful market research solutions that adapt to the ever-changing demands of businesses around the globe. We want our clients to have information that can be used to act upon their strategic initiatives. We, therefore, aim to be your trustworthy partner within dynamic business settings through excellence and innovation. By offering comprehensive market intelligence, our company enables corporate organizations to make informed choices, drive growth, and stay ahead in competitive market.